ArticleJournal of the Pediatric Infectious Diseases Society2015
A Prospective, International Cohort Study of Invasive Mold Infections in Children.
Article in Journal of the Pediatric Infectious Diseases Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Infectious Complications in Paediatric Haematopoetic Cell Transplantation for Acute Lymphoblastic Leukemia: Current Status.Frontiers in pediatrics · 2021Pooled it
- Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review.Journal of the Pediatric Infectious Diseases Society · 2018Pooled it
- Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease.Antimicrobial agents and chemotherapy · 2026Trial
- Trial
- Evaluation of the Clinical Characteristics and Survival of Pediatric Patients with Invasive Aspergillosis: A 12-year Retrospective Cohort Study.Mycopathologia · 2026Article
- Fungal Infections in Pediatric Patients With Hematologic Malignancies and Stem Cell Transplantation: Impact on the Upper and Lower Respiratory Systems.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Pediatric vs. Adult Invasive Aspergillosis in Cancer and Hematopoietic Transplant Patients: Insights from a Matched Cohort at a Tertiary Cancer Center.Journal of fungi (Basel, Switzerland) · 2025Article
- Observational
- The Burden of Neonatal Invasive Candidiasis in Low- and Middle-income Countries: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2025Article
- Non-Candida mycosis in Gulf Cooperation Council (GCC) countries: perspective of a low-incidence region.BMC infectious diseases · 2025Review
- Risk factors for identifying pulmonary aspergillosis in pediatric patients.Frontiers in cellular and infection microbiology · 2025Article
- Evaluation of the combined efficacy of inhibitors of heat shock protein 90 and calcineurin with commonly used antifungals againstCurrent medical mycology · 2025Article
- Invasive Mold Infections in Children: Navigating Troubled Waters with a Broken Compass.Infectious diseases and therapy · 2023Review
- Liposomal amphotericin B-the present.The Journal of antimicrobial chemotherapy · 2022Article
- Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.Antimicrobial agents and chemotherapy · 2022Review
- Epidemiology of Fungal Colonization in Children Treated at the Department of Oncology and Hematology: Single-Center Experience.International journal of environmental research and public health · 2022Article
- Fungal Infection Testing in Pediatric Intensive Care Units-A Single Center Experience.International journal of environmental research and public health · 2022Article
- Combined Effect ofFrontiers in pediatrics · 2022Article
- Characteristics of antifungal utilization for hospitalized children in the United States.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia.Hematology. American Society of Hematology. Education Program · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 7 countries.
Funding
Abstract
backgroundInvasive mold infections (IMIs) are a leading cause of mortality in immunocompromised children, yet there has never been an international epidemiologic investigation of pediatric IMIs.
methodsThis international, prospective cohort study was performed to characterize the epidemiology, antifungal therapy, and outcomes of pediatric IMIs. Children (≤18 years) with proven or probable IMIs were enrolled between August 2007 and May 2011 at 22 sites. Risk factors, underlying diagnoses, and treatments were recorded. Outcomes were assessed at 12 weeks after diagnosis using European Organization for Research and Treatment of Cancer/Mycoses Study Group response criteria.
resultsOne hundred thirty-one pediatric patients with IMIs were enrolled; the most common IMI was invasive aspergillosis ([IA] 75%). Children with IA and those with other types of IMIs had similar underlying risk factors, except that children with IMIs caused by non-Aspergillus species were more likely to have received mold-active antifungal agents preceding diagnosis. The most commonly used antifungal classes after diagnosis were triazoles (82%) and polyenes (63%). Combination therapy was used in 53% of patients. Use of combination therapy was associated with an increased risk of adverse events (risk ratio, 1.98; 95% confidence interval, 1.06-3.68; P = .031), although there was no detectable difference in outcome.
conclusionsAlthough risk factors for IMIs are similar across specific subtypes, preceding antifungal therapy may be an important modifier. Combination antifungal therapy requires further study to determine its true risks and benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.